The importance of patient preference in the decision to screen for prostate cancer
Journal of General Internal MedicinePublished 1 June 1996
Ann Barry Flood, John E. Wennberg, Robert F. Nease, Floyd J. Fowler, Jiao Ding, Lynda M. Hynes
Citations273
SJR quartileQ1
SJR score1.99
SNIP1.71
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
Preference regarding cancer screening and treatment is greatly affected by information about medical uncertainties, and informed patient choices vary, PSA screening decisions should incorporate individual preferences.
Abstract
Preference regarding cancer screening and treatment is greatly affected by information about medical uncertainties. Because informed patient choices vary. PSA screening decisions should incorporate individual preferences.
Keywords
MedicineHealth Professions
The Journal of UrologyComparison of Digital Rectal Examination and Serum Prostate Specific Antigen in the Early Detection of Prostate Cancer: Results of a Multicenter Clinical Trial of 6,630 Men
1,422 Citations1994William J. Catàlona, John P. Richie +11 more
The use of PSA in conjunction with digital rectal examination enhances early prostate cancer detection and should be considered if either the PSA level is greater than 4 micrograms/l or digital rectAL examination is suspicious for cancer, even in the absence of abnormal transrectal ultrasonography findings.
CancerLocalized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer
797 Citations1993Thomas A. Stamey, Fuad S. Freiha +4 more
The authors calculated the probability at birth of having a diagnosis of prostate cancer within a man's life to be 8.8% and subtracted the incidence of microscopic Stage A cancers too small to ever be clinically significant.
UrologyPatient-re ported complications and follow-up treatment after radical prostatectomy
640 Citations1993Floyd J. Fowler, Michael J. Barry +4 more
Estimates of complication and follow-up treatment rates are generally higher, and almost certainly more representative for older men, than estimates previously published.
New England Journal of MedicineA Comparison of Transurethral Surgery with Watchful Waiting for Moderate Symptoms of Benign Prostatic Hyperplasia
611 Citations1995John H. Wasson, Domenic J. Reda +4 more
For men with moderate symptoms of benign prostatic hyperplasia, surgery is more effective than watchful waiting in reducing the rate of treatment failure and improving genitourinary symptoms.
JAMAHigh 10-Year Survival Rate in Patients With Early, Untreated Prostatic Cancer
467 Citations1992Jan‐Erik Johansson
The low disease-specific mortality rate, especially in patients with highly and moderately differentiated tumors, means that any local or systemic therapy intended for patients with early prostatic cancer must be evaluated in clinical trials with untreated controls for comparison.
JNCI Journal of the National Cancer InstituteEffects of Individualized Breast Cancer Risk Counseling: a Randomized Trial
440 Citations1995Caryn Lerman, Edward D. Lustbader +5 more
Attention to the psychological aspects of breast cancer risk will be critical in the development of risk-counseling programs that incorporate testing for the recently cloned breast cancer susceptibility gene, BRCA1 (and BRCa2 when that gene has also been cloned).
New England Journal of MedicineIncorporating Patients' Preferences into Medical Decisions
412 Citations1994Jerome P. Kassirer
A decision analysis is presented of the choice between heparin alone and streptokinase plusHeparin in the treatment of deep venous thrombosis and the result helps identify a patient's preferences scrupulously.
JNCI Journal of the National Cancer InstitutePerceptions of Breast Cancer Risk and Screening Effectiveness in Women Younger Than 50 Years of Age
410 Citations1995William C. Black, Robert F. Nease +1 more
A balanced presentation of information about breast cancer risk and screening effectiveness may improve decision making for women younger than 50 years of age and reduce their anxiety about Breast cancer, regardless of whether they choose to be screened.
CancerObservations on the doubling time of prostate cancer.The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume
404 Citations1993Hans‐Peter Schmid, John E. McNeal +1 more
This work has shown that changes in PSA in untreated patients should reflect tumor growth rate and the shape of the growth curve, and aims to clarify the role of serum marker prostate‐specific antigen in prostate cancer diagnosis.
CA A Cancer Journal for CliniciansDefining and updating the American Cancer Society guidelines for the cancer-related checkup: prostate and endometrial cancers
305 Citations1993Curtis Mettlin, Graeme Jones +3 more
Annals of Internal MedicineProstate Cancer Screening: What We Know and What We Need To Know
276 Citations1993Barnett S. Kramer, Martin L. Brown +3 more
A number of scientific and economic uncertainties exist about the wisdom of widespread implementation of the PSA assay for screening, and these uncertainties justify a definitive randomized trial to determine whether screening for prostate cancer would reduce mortality from the disease.
Archives of Family MedicineA structured literature review of treatment for localized prostate cancer. Prostate Disease Patient Outcome Research Team
215 Citations1993John H. Wasson
Until better scientific evidence is available, patients and their physicians cannot make informed choices based on knowledge of the benefits of radical prostatectomy, radiation, or watchful waiting.
BMJDetection of prostate cancer
46 Citations1995Fritz H. Schröder
The study group concluded that the majority of prostate cancers have spread beyond the gland when first diagnosed using the conventional detection method, digital rectal examination, and the most promising alternative for improving the prognosis of patients is to enhance early detection.
European UrologySerum Prostate-Specific AntigenDiscriminates Weakly betweenMen with Benign ProstaticHyperplasia and Patients withOrgan-Confined Prostate Cancer
45 Citations1994Peter Sershon, Michael J. Barry +1 more
It is suggested that serum PSA has only a modest ability to distinguish men with BPH from patients with organ-confined prostate cancer, and some symptomatic BPH patients choosing a non-TURP therapy may harbor a clinically significant prostate cancer despite being evaluated with a serum PSC determination.
The Journal of UrologyProstate Specific Antigen Cannot Distinguish Stage T1a (A1) Prostate Cancer from Benign Prostatic Hyperplasia
42 Citations1994Jeffrey M. Monda, Michael J. Barry +1 more
It is suggested that the routine use of serum PSA does not decrease the prevalence of stage T1a prostate cancer and that PSA may decrease thePrevalence ofstage T1b tumors but a larger study would be necessary to document this finding.
The Journal of UrologyThe Use of Prostate Specific Antigen for Prostate Cancer Screening: A Managed Care Perspective
26 Citations1994Matthew R Handley, Michael E. Stuart
If PSA screening had continued at the peak rate, the cascade of intervention initiated by screening would have resulted in significant complications and approximately $4,800,000 in increased costs.
UrologyWatchful waiting for early stage prostate cancer
26 Citations1994Jan‐Erik Johansson
There are many uncertainties in localized prostatic cancer and a main question today is how to treat these patients, and the treatment policy varies between both individuals and institutions.
JAMAScreening for Prostate Cancer
13 Citations1994Gerald W. Chodak
Performing a one-time screen using digital rectal examination and PSA is predicted to increase life expectancy by 0.6 and 1.7 days for 50-and 70-year-old men, respectively, the first study published using a Markov model to predict the outcomes from screening using PSA.